Eli Lilly (LLY) Debt to Equity (2016 - 2025)
Eli Lilly's Debt to Equity history spans 17 years, with the latest figure at $1.6 for Q4 2025.
- For Q4 2025, Debt to Equity fell 32.05% year-over-year to $1.6; the TTM value through Dec 2025 reached $1.6, down 32.05%, while the annual FY2025 figure was $1.6, 32.05% down from the prior year.
- Debt to Equity reached $1.6 in Q4 2025 per LLY's latest filing, down from $1.79 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $307.65 in Q1 2024 to a low of -$22.7 in Q2 2025.
- Average Debt to Equity over 5 years is $36.66, with a median of $2.41 recorded in 2021.
- Peak YoY movement for Debt to Equity: crashed 258.63% in 2022, then skyrocketed 6253.86% in 2024.
- A 5-year view of Debt to Equity shows it stood at $96.15 in 2021, then crashed by 105.61% to -$5.39 in 2022, then soared by 164.56% to $3.48 in 2023, then crashed by 32.25% to $2.36 in 2024, then crashed by 32.05% to $1.6 in 2025.
- Per Business Quant, the three most recent readings for LLY's Debt to Equity are $1.6 (Q4 2025), $1.79 (Q3 2025), and -$22.7 (Q2 2025).